ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2018.6202 ETM-0-0-6202 Articles Effect of thrombelastography on timing of coronary artery bypass grafting YangZhiyuan XieZhouliang PeiXueliang QuanXiaoqiang FengDeguang Department of Cardiovascular Surgery, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China Correspondence to: Dr Zhouliang Xie, Department of Cardio-vascular Surgery, Henan Provincial People's Hospital, 7 Weiwu Road, Zhengzhou, Henan 450003, P.R. China, E-mail: xiezhouliang2016@163.com 08 2018 21 05 2018 16 2 579 584 31082017 28032018 Copyright: © Yang et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The guiding value of thrombelastography (TEG) on the selection of surgical timing for patients scheduled for coronary artery bypass grafting (CABG) was investigated. A total of 90 subjects with acute coronary syndrome (ACS) treated between February 2014 and December 2016 in Henan Provincial People's Hospital were recruited. The patients received dual antiplatelet therapy (DAPT) and were scheduled for CABG. Subjects were randomly allocated into two groups, TEG group (n=45) and non-TEG group (n=45). Patients in the TEG group withheld medications at 24 h prior to surgery and received TEG examination. Based on maximum amplitude of adenosine diphosphate (MAADP), subjects were further grouped into three sub-groups with MAADP <35 mm, 35–50 mm, and >50 mm, and accordingly received CABG within 1 day, 3–5 days and 5 days later, respectively. Subjects in the control group (non-TEG group) received CABG 5–7 days after medication withdrawal. Chest drainage volume within 24 h after surgery and red blood cell transfusion during perioperative period were compared. Other recorded parameters were incubation period, intensive care unit length of stay, hospital stay, incidence of 30-day adverse events and readmission rate. The average waiting time before CABG for patients of TEG group was shorter compared with the commonly recommended time. The red blood cell transfusions during perioperative period of subjects in TEG group and non-TEG group were significantly different (P=0.23). The median hospital stay of subjects in TEG group was shorter than that of non-TEG group (P=0.037). The bleeding amount of patients in TEG group was 220.16±80.56 ml, which was significantly lower than that of non-TEG group (435.29±90.16). The difference was statistically significant (P=0.032). The results suggested that TEG assay-based evaluation of platelet function for patients scheduled for CABG reasonably guides surgeons with appropriate surgical timing and reduces the amount of time patients wait to be treated.

 thrombelastography coronary artery bypass grafting surgical timing Introduction

Dual antiplatelet therapy (DAPT) has been considered of high value in relieving the hypercoagulable states in patients with acute coronary syndrome (ACS) (1,2). However, for patients scheduled for off-pump coronary artery bypass grafting (CABG), DAPT poses strong risk for perioperative bleeding in patients with CABG (3). Moreover, consumption of coagulation factor during cardiopulmonary bypass, dilution of fibrinogen and platelets, combined with other risk factors such as heparin and decreased body temperature, all result in depression on coagulation function, thus increasing the risk of perioperative bleeding, blood transfusion, postoperative mortality and rate of complication (4).

There has been no consensus on the timing of ACS patients receiving DAPT treatment. Previous findings showed that there was no significant difference of bleeding event between ACS patients withholding clopidogrel ≤5 or >5 days before PCI (5). While according to class I recommendation by American College of Cardiology Foundation/American Heart Association (ACCF/AHA), patients should withhold clopidogrel for 5 days before CABG in order to restore the platelet function (6). Whereas, Class IIb recommendation by expert team on blood conservation of Society of Thoracic Surgeons (STS) suggested that platelet function test should be performed, based on which the surgical timing will be determined for patients receiving DAPT treatment (7). Therefore, in the present study, platelet function was measured using a TEG5000 thrombelastograph analyzer and the surgical timing was determined based on the measured maximum amplitude of adenosine diphosphate (MAADP) values.

 Materials and methods <sec> <title>Clinical material

In total, 90 subjects (including 47 males and 43 females; aged 42 to 80 years; average age, 61.2±10.2 years) with ACS treated from February 2014 to December 2016 in cardiothoracic surgery department of Henan Provincial People's Hospital (Zhengzhou, China) were recruited. The patients received DAPT and were scheduled for CABG. All the patients received regular DAPT treatment before surgery of aspirin (100 mg/day) and clopidogrel (75 mg/day) (aspirin was purchased from Chifeng Wanze Pharmaceutical Co., Ltd. (Chifeng, China; NMPN. H10940218); clopidogrel was purchased from Wuhan Wuyao Pharmaceutical Co. Ltd. (Wuhan, China; NMPN. H20123155). Subjects were randomly allocated into two groups, thrombelastography (TEG) group (n=45) and non-TEG group (n=45), respectively in order of admission, and 45 patients (hereinafter referred to as TEG group/study group) withheld medications 24 h before surgery and received TEG examination. The TEG group included 23 males and 22 females, aged 43 to 79 years (average age, 61.3±9.8 years). The other 45 patients (including 24 males and 21 females; aged 42–80 years; average age, 61.2±11.3 years) received surgery after 5–7 days of medication withdrawal. For the TEG group, based on MAADP, subjects were further grouped into 3 sub-groups with MAADP <35 mm, 35–50 mm, and >50 mm, respectively, then accordingly, received CABG within 1 day, 3–5 days and 5 days after withdrawal. The patients were treated with off-pump CABG under general anesthesia. Heparin was given routinely for antithrombotic use.

Exclusion criteria for the study were: Patients that received emergency surgery after failing percutaneous coronary intervention; patients in need of either valve repair or valve replacement; patients with hematocrit (PCV) <30%; patients with coagulation disorders, renal insufficiency (creatinine clearance rate <30 ml/min), or viral hepatitis.

The study protocol was reviewed and approved by the ethics committee of Henan Provincial People's Hospital. The patients and families were fully informed of the study and signed the informed consent. No statistically significant difference was found between the two groups regarding age, sex ratio, prevalence of hypertension, diabetes, medical history of myocardial infarction (MI), preoperative ejection fraction and preoperative drug use (P>0.05). The general preoperative clinical data of the two groups of patients are presented in Table I.

 Examination methods

A TEG 5000 thrombelastograph analyzer (Haemoscope Corporation, Niles, IL, USA) was used for the examination with ADP as inducer. The analyzer was operated under normal conditions, and relevant reagents and the instrument were operated as per instructions (Fig. 1). For the heparinized blood samples, at least 3 ml peripheral blood was collected with heparinized anticoagulant tube followed by adequate stirring. Samples were sent for testing immediately. Examination were completed within 3 h after sample collection. For the TEG test results, MAADP, was recorded. Patients of TEG group were tested after 24 h of medication withdrawal. Based on the screening results of MAADP, patients of TEG group were further grouped into three sub-groups with MAADP <35 mm (patients with platelet hyperreactivity), 35–50 mm (patients with medium platelet activity), and >50 mm (patients with platelet hyporeactivity), respectively. Accordingly, subjects of the 3 sub-groups received CABG within 1 day, 3–5 days and 5 days after withdrawal. Patients in the control group commonly received surgery 5–7 days after medication withdrawal. Platelet inhibition rate induced by AA and ADP was calculated by computer software. At the same time, MA-Thrombin, MA induced by AA (MA-AA), MA induced by ADP (MAADP) were recorded.

 Observation parameter

Chest drainage volume within 24 h (primary endpoint) and red blood cell transfusion in the perioperative period (secondary endpoint) were compared. Incubation period, intensive care unit (ICU) length of stay (LOS), hospital stay, incidence of 30-day adverse events, the amount of bleeding and readmission rate of the subjects in the two groups were reported.

 Statistical analysis

IBM SPSS Statistics 21 software (IBM Corp., Armonk, NY, USA) was used to analyze the data. Quantitative data are described with difference between the two groups as mean ± standard deviation, and assessed using t-test. Numeration data variables were expressed as frequencies and percentages and performed with χ2 test to compare the difference. The one-way analysis of variance (ANOVA) with the least significant difference test was used to correct the variables. Count data were expressed by percentage (%) and assessed with χ2 test. Difference with P<0.05 was considered statistically significant.

 Results <sec> <title>Waiting time before surgery for TEG group

Based on screening results of MAADP, patients of the TEG group for elective CABG were grouped into three sub-groups with MAADP <35 mm, 35–50 mm, and >50 mm, respectively. Accordingly, subjects of 3 sub-groups received CABG within 1 day, 3–5 days and 5 days after withdrawal. Patients in the control group commonly received surgery 5–7 days after medication withdrawal. The average waiting time of patients in TEG group before CABG was 3.2 days. The detailed screening results of MAADP and waiting time prior surgery of the 3 sub-groups of patients are shown in Fig. 2. Among patients of TEG group with MAADP <35 mm, one patient received surgery earlier than scheduled. The matching rate between scheduled and actual waiting time was 86.67% (13/15). Among patients in TEG group with MAADP of 35–50 mm scheduled to receive elective CABG within 3–5 days, two received surgery earlier than scheduled, resulting in a matching rate between scheduled and actual waiting time of 90.47% (19/21). Among patients with MAADP >50 mm and scheduled to receive CABG within 1 day, four patients received surgery after the scheduled time, resulting in a matching rate between scheduled and actual waiting time of 44.44% (4/9).

 Comparison of the 24-h chest drains after surgery between the TEG and non-TEG groups

Statistical analysis was conducted with ANOVA-corrected variables and the results showed that there was no significant difference of the median 24-h chest drain volumes of patients between the TEG and non-TEG groups (435 and 488 ml for TEG and non-TEG group, respectively; P=0.287). Further analysis revealed that among patients of the three MAADP-based sub-groups of the TEG group, the 24-h postoperative chest drain volume of patients receiving surgery after 5 days was higher than those receiving CABG in 3–5 days, which was higher than those received within 1 day. However, no statistical difference was detected by comparing the chest drains of the three sub-groups (P=0.532). Detailed results are presented in Fig. 3.

 Comparison of red cell transfusion during perioperative period between patients in TEG and non-TEG groups

No statistically significant difference was detected between TEG and non-TEG groups by comparing the average red blood cell transfusion volumes during perioperative period, which were 494.7 and 554.2 ml, respectively (P=0.23). With variables being corrected with ANOVA test, the average red blood cell transfusion volumes during perioperative period of TEG and non-TEG groups were 495.2 and 555.3 ml, respectively. No statistically significant difference was detected with bilateral U-test (P=0.06).

 Comparison of clinical endpoint events between patients in TEG and non-TEG groups

The median hospital stay of patients in TEG group was 24 days, significantly shorter than that in non-TEG group (P=0.037). The bleeding amount of patients in TEG group was 220.16±80.56 ml, which was significantly lower than that of non-TEG group (435.29±90.16). The difference was statistically significant (P=0.032). No statistically significant differences were found by comparing the perioperative chest drains, incubation period, ICU LOS, 30-day mortality, 30-day readmission rate (P>0.05). Detailed results are listed in Table II.

 Discussion

Perioperative use of antiplatelet therapy is important for patients undergoing CABG. DAPT combining two medications of different mechanisms, aspirin with clopidogrel, is the most common antiplatelet therapy for patients with ACS. Specifically, with aspirin mainly inhibiting COX-1 (cyclooxygenase 1) by inhibiting the platelet thrombus formation and clopidogrel inhibiting the P2Y receptor on platelets, both medications irreversibly inhibit the platelet function (8,9). Therefore, for ACS patients undergoing CABG surgery, reasonable selection of surgical timing and monitoring of platelet function is important to reduce perioperative bleeding, postoperative morbidity and mortality. Latest comparison of guidelines showed that patients taking clopidogrel are mostly recommended to have the surgery after 5 days of medication withdrawal. However, considering the individual difference in clopidogrel metabolism, platelet function in some patients may have already restored within 5 days of medication withdrawal. With such fact taken into consideration, preoperative monitoring of platelet function provides significant clinical value for selecting surgical time points, which is also considered as a safer approach (10,11).

TEG analyzer is a monitor recording dynamic processes including blood coagulation, platelet aggregation, coagulation and fibrinolysis. It has become an important indicator of blood coagulation function during liver transplantation, and bypass surgery. It has been widely used in the assessment of antithrombotic therapy for coronary heart disease, platelet activity and antiplatelet effect in the world. But there are few studies in China. It is used in this study to evaluate the inhibition of platelets after treatment. Inhibition of platelet aggregation can be achieved by inhibition of cyclooxygenase pathway reducing the formation of TXA2, or inhibiting ADP receptor pathway. TEG platelet aggregation AA and ADP induced pathway is based on this. It was found that for PCI patients with high platelet reactivity detected by TEG, cTnI, CK-MB level increased significantly after PCI surgery. The incidence of clinical ischemia was increased 6 months after surgery, indicating that TEG is reliable for determining the high platelet reactivity caused by drug resistance after the operation.

Platelets play important roles in blood coagulation and determine approximately 80% of the strength of the clot. According to the response to antiplatelet therapy, patients can be categorized as platelet hyperreactivity (bleeding tendency), medium platelet activity, and platelet hyporeactivity (resistance to antiplatelet therapy) in clinic (12). Fitchett et al (13) performed blood platelet aggregation test using optical microscopy with varying inducers. Hyporeactivity to aspirin (aspirin resistance) was defined as platelet aggregation rate when taking aspirin ≥50% with AA as inducer, and hyporeactivity to clopidogrel (clopidogrel resistance) was defined as platelet aggregation of ≥70% with ADP as inducer. According to Fitchett et al, the MAADP value was defined as 35 mm and 50 mm as transition point, TEG 5000 thrombelastograph analyzer was used to measure the platelet function and evaluate the medication-induced platelet inhibition. Based on the preoperative screening results of MAADP, patients in TEG group were allocated in to three sub-groups with MAADP <35 mm, 35–50 mm, and >50 mm, respectively. Accordingly, patients of these three sub-groups received CABG within 1 day of medication withdrawal, after 3–5 days of medication withdrawal, and after 5 days of withdrawal, respectively. Patients of the TEG group waited for an average of 3.2 days before CABG, 36% shorter than 5 days as recommended by the guideline. Major parameters tested by TEG-measured platelet thrombelastogram included platelet inhibition rate (AA/ADP inhibition rate), MAADP and MACK (14). Platelet inhibition rate is a reference index of efficiency of antiplatelet drugs. Usually, inhibition of AA platelet stimulation <50% or ADP% inhibition <30% suggested inadequate antiplatelet efficacy; inhibition rate >76% indicated relatively high platelet inhibition and clinical attention should be paid to potential risk of bleeding (15,16). For patients taking antiplatelet medication before surgery, surgical timing can be selected according to the inhibition rate so as to better prevent the preoperative thrombus formation and intraoperative massive hemorrhage. MAADP provides significant value by guiding the selection of surgical timing. Typically, for elective CABG, patients with MAADP <35 mm should wait for more than 5 days before surgery; patients with MAADP ranged 35 mm-50 mm should wait for 3–5 days prior to surgery; and patients with MAADP >50 mm are allowed to receive the surgery on the same day as medication withdrawal (4,17). In the present study, no significant difference was observed when comparing the postoperative 24-h chest drains among the three TEG sub-groups. In addition, no statistically significant difference was found by comparing the 24-h chest drains, perioperative average red blood cell transfusion volume, incubation period, ICU LOS, 30-day mortality, and 30-day readmission rate. These results showed that TEG-measured platelet function successfully guided the appropriate surgical timing, which resulted in comparable outcome and adverse event rates and reduced waiting time compared with patients received CABG 5 days after medication withdrawal. More importantly, TEG-based platelet function measurement is featured with easy operation, high repeatability, and stable performance. Only trace amount of whole blood was required without any sample treatment. Results can be achieved within short test time down to 30 min. Simultaneous categorized detection is possible for combined medication, providing test results free from effect of heparin drugs (18,19). MAADP value, MAAA, MACK and platelet inhibition rate measured by TEG are all objective parameters adequately reflecting the drug-induced platelet inhibition, which provides important value for patients in medical and surgical departments (20). Physicians may also benefit from the above-mentioned parameters by adjusting dosage to reduce risk of bleeding and thrombosis. Surgeons can guide the surgical and postoperative examination according to the indexes above so as to reduce the risk of perioperative bleeding and incidence of complications.

In summary, TEG-based platelet function evaluation for patient elective for CABG can reasonably guide the surgeons in surgical timing and reduce the waiting time prior to operation, without significant increase of postoperative bleeding volume and blood transfusion volume, as well as postoperative incidence rate of adverse events.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

ZY collected and analyzed the general data. ZX performed TEG test. XP and XQ recorded MA-thrombin, MA induced by AA, MADP. ZY and DF recorded and interpreted incubation period, intensive care unit (ICU) length of stay (LOS), hospital stay, incidence of 30-day adverse events, the amount of bleeding and readmission rate. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The study protocol was reviewed and approved by the Ethics Committee of Henan Provincial People's Hospital. The patients and families were fully informed of the study and signed the informed consent.

 Consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References RoffiMGencerBStoreyRFAndreottiFPatronoCClinical perspectives and pearls from the 2015 ESC NSTE-ACS guidelinesCurr Cardiol Rep1848201610.1007/s11886-016-0722-027068306 YanagawaBRuelMBonneauCLeeMMChungJAl ShouliSFaganAAl KhalifaAWhiteCWYamashitaMHDual antiplatelet therapy use by Canadian cardiac surgeonsJ Thorac Cardiovasc Surg15015481554.e3201510.1016/j.jtcvs.2015.08.06626395051 BarbieriLPergoliniPVerdoiaMRollaRNardinMMarinoPBellomoGSuryapranataHde LucaGNovara Atherosclerosis Study Group (NAS)Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelorVascul Pharmacol791115201610.1016/j.vph.2015.10.00626518440 JanssenPWAClaassensDMFWillemsenLMBergmeijerTOKleinPTen BergJMPerioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centresNeth Heart J25482489201710.1007/s12471-017-1006-z28612281 PilgrimTWindeckerSAntiplatelet therapy for secondary prevention of coronary artery diseaseHeart10017501756201410.1136/heartjnl-2013-30539925037531 LevineGNBatesERBittlJABrindisRGFihnSDFleisherLAGrangerCBLangeRAMackMJMauriL2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesJ Thorac Cardiovasc Surg15212431275201610.1016/j.jtcvs.2016.07.04427751237 van DiepenSFusterVVermaSHamzaTHSiamiFSGoodmanSGFarkouhMEDual antiplatelet therapy versus aspirin monotherapy in diabetics with multivessel disease undergoing CABG: FREEDOM insightsJ Am Coll Cardiol69119127201710.1016/j.jacc.2016.10.04328081820 VermaSGoodmanSGMehtaSRLatterDARuelMGuptaMYanagawaBAl-OmranMGuptaNTeohHShould dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trialsBMC Surg15112201510.1186/s12893-015-0096-z26467661 ChengJWTicagrelor: Oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromesClin Ther3412091220201210.1016/j.clinthera.2012.04.00522521881 KaronBSTolanNVKochCDWockenfusAMMillerRSLingineniRKPruthiRKChenDJaffeASPrecision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapyClin Chem6015241531201410.1373/clinchem.2014.22633225281703 TantryUSBonelloLAradiDPriceMJJeongYHAngiolilloDJStoneGWCurzenNGeislerTTen BergJConsensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleedingJ Am Coll Cardiol6222612273201310.1016/j.jacc.2013.07.10124076493 BombROliphantCSKhouzamRNDual antiplatelet therapy after coronary artery bypass grafting in the setting of acute coronary syndromeAm J Cardiol116148154201510.1016/j.amjcard.2015.03.05025933730 FitchettDEikelboomJFremesSMazerDSinghSBittiraBBristerSGrahamJGuptaMKarkoutiKDual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular SocietyCan J Cardiol25683689200910.1016/S0828-282X(09)70527-619960127 DiasJDNoremKDoorneweerdDDThurerRLPopovskyMAOmertLAUse of thromboelastography (TEG) for detection of new oral anticoagulantsArch Pathol Lab Med139665673201510.5858/arpa.2014-0170-OA25927150 JamesKBertojaEO'BeirneJMallettSUse of thromboelastography PlateletMapping to monitor antithrombotic therapy in a patient with Budd-Chiari syndromeLiver Transpl163841201010.1002/lt.2193320035517 RamakrishnaHGutscheJTPatelPAEvansASWeinerMMorozowichSTGordonEKRihaHBrackerJGhadimiKThe year in cardiothoracic and vascular anesthesia: Selected highlights from 2016J Cardiothorac Vasc Anesth31113201710.1053/j.jvca.2016.10.00928041810 HanssonECMalmCJHesseCHornestamBDellborgMRexiusHJeppssonAPlatelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgeryEur J Cardiothorac Surg51633637201728007881 TangXFHanYLZhangJHWangJZhangYXuBGaoZQiaoSBChenJWuYComparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrelChin Med J (Engl)128774779201510.4103/0366-6999.15261125758271 YaoYZhangJHTangXFHeCMaYLXuJJSongYLiuRMengXMSongLHead to head comparison of two point-of-care platelet function tests used for assessment of on-clopidogrel platelet reactivity in Chinese acute myocardial infarction patients undergoing percutaneous coronary interventionChin Med J (Engl)12922692274201610.4103/0366-6999.19066427647183 BochsenLWiinbergBKjelgaard-HansenMSteinbrüchelDAJohanssonPIEvaluation of the TEG platelet mapping assay in blood donorsThromb J53200710.1186/1477-9560-5-317311677

Schematic illustration of TEG platelet measurement. Different activators were used to detect heparinized blood samples. TEG, thrombelastography; MAADP, maximum amplitude of adenosine diphosphate.

Box-plot indicating the scheduled and actual waiting time of patients in three sub-groups grouped by MAADP before CABG and non-TEG group. MAADP <35 mm, the waiting time more than 5 days; 35 mm ≤MAADP <50 mm, the waiting time 3–5 days; MAADP 50 mm, the waiting time 1 day. MAADP, maximum amplitude of adenosine diphosphate; CABG, coronary artery bypass surgery; TEG, thrombelastography.

Box-plot indicating the chest drainage volume of patients in TEG and non-TEG groups. No statistical difference is observed by comparing the chest drains between the two groups (P=0.287). In addition, no statistically significant difference is found in the chest drains of patients of three sub-groups in TEG group were comparable (P=0.532). TEG, thrombelastography.

General preoperative condition of the two groups of patients undergoing CABG.

Items Total (n=90) TEG group (n=45) Non-TEG group (n=45) χ2/t P-value
Age (years, mean ± SD) 60.7±9.8 61.2±9.9 60.3±10.1 0.945 0.31
Sex, n (%) 47 (52.22) 23 (51.11) 24 (53.33) 0.845 0.34
Hypertension, n (%) 71 (78.89) 35 (77.78) 36 (80.0) 0.942 0.33
Diabetics, n (%) 38 (42.22) 19 (42.22) 20 (44.44) 0.415 0.55
MI history, n (%) 29 (32.22) 15 (33.33) 14 (31.11) 0.428 0.52
Preoperative ACS, n (%) 37 (41.11) 19 (42.22) 18 (40.0) 0.275 0.74
Ejection fraction (%, mean) 52.3±12.1 51.3±12.2 53.4±12.1 0.439 0.54
Unfractionated heparin (24 h before surgery), n (%) 31 (34.44) 15 (33.33) 16 (57.78) 0.117 0.92
ACEIs/ARBs, n (%) 62 (68.89) 30 (66.67) 32 (71.11) 0.029 0.86
β-blocker, n (%) 68 (75.56) 33 (73.33) 35 (77.77) 0.569 0.51
Statins, n (%) 9 (10.0) 4 (8.89) 5 (11.11) 0.023 0.48
PPIs, n (%) 9 (10.0) 4 (8.89) 5 (11.11) 0.339 0.75
Pre-operative INR 0.91±0.18 0.93±0.21 0.94±0.15 0.328 0.78
APTT (sec) 29.42±2.13 28.72±2.51 28.62±2.25 0.143 0.89

CABG, coronary artery bypass surgery; TEG, thrombelastography; MI, myocardial infarction; ACS, acute coronary syndrome; ACEI, angiotension converting enzyme inhibitors; ARB, angiotensin receptor blocker; PPI, proton pump inhibitors; INR, international normalized ratio; APTT, activated partial thromboplastin time.

Comparison of clinical endpoint events between patients in TEG and non-TEG groups.

Item TEG group (n=45) Non-TEG group (n=45) χ2/t value P-value
Perioperative chest drain (ml, median) 438 489 1.037 0.29
Incubation period (hour, median) 21 22 0.835 0.46
Hospital stay (day, median) 24 32a 2.076 0.04
ICU length of stay (day, median) 2 2 0.843 0.47
Second thoracotomy, n (%) 0 (0) 0 (0) 0.081 1.00
30-day mortality, n (%) 0 (0) 0 (0) 0.081 1.00
30-day readmission rate, n (%) 7 (15.56) 8 (17.78) 0.337 0.75
Amount of bleeding 220.16±80.56 435.29±90.16a 2.213 0.03

P<0.05. TEG, thrombelastography; ICU, intensive care unit.